Prescription drug Published: RCT evidence Extensive real-world use

Tirzepatide Dosing Guide: Titration, Vial Math & the Interactions That Matter

Tirzepatide is the strongest approved drug in the weight class — a dual GIP/GLP-1 agonist that beat semaglutide head-to-head. It is also the one with the interaction people miss: it can make birth control pills less reliable. This guide covers the titration that works, the vial math, what SURMOUNT actually showed, and the practical rules the label buries in section 7.

Also known as Mounjaro, Zepbound, GLP-2 TZ

Educational research reference Last reviewed August 2026 Metabolic & Weight

Tirzepatide quick start

Route: Subcutaneous injection, once weekly. Commercial pens (Mounjaro, Zepbound) are ready to use; vial-format product — grey-market material often listed as "GLP-2 TZ" — is reconstituted and drawn with an insulin syringe.
Dose context: 2.5 mg weekly for 4 weeks, then stepwise up through 5, 7.5, 10, 12.5 to a 15 mg maximum. Most people find their maintenance dose between 5 and 15 mg. The 2.5 mg start is for adaptation, not effect.
Measure: A 30 mg vial in 1.0 mL gives 30 mg/mL — the 2.5 mg starting dose is about 8 units on a U-100 syringe, and the full 15 mg dose is 50 units.
Cycle context: Not cycled. SURMOUNT-1 ran 72 weeks continuously; stopping typically reverses the loss. Long-term therapy is the model.
Status: FDA-approved: type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023), with an obstructive sleep apnea indication added later. Prescription only.

These are the numbers people actually run, drawn from the published record and from what the community has settled on over time. Educational reference, not medical advice — a starting point to work from, and one you can adjust as you learn how you respond.

Dosing context and schedule

What follows is drawn from the published record and from what the community has settled on. Reference points, not prescriptions — your situation is yours.

Phase	Dose	Volume	Units (U-100)	Note
Weeks 1–4	2.5 mg/week	0.08 mL	8 units	30 mg vial in 1.0 mL. Adaptation dose — judge nothing here.
Weeks 5–8	5 mg/week	0.17 mL	17 units	The first working dose. A common long-term parking spot.
Weeks 9–12	7.5 mg/week	0.25 mL	25 units	Step only if loss has stalled and the gut is quiet.
Weeks 13–16	10 mg/week	0.33 mL	33 units	A maintenance dose from the trials.
Week 17+	12.5–15 mg/week	0.42–0.50 mL	42–50 units	The top of the label schedule. Diminishing returns are real above 10 mg for many people.

Cycle structures

Approach	Duration	Review point	Note
Label titration	20 weeks to 15 mg	Every 4 weeks	Each step held a minimum of 4 weeks per the label.
Slow titration	6–12 months	Each step change	The community default. Hold each dose until side effects are boring; many people never leave 5–7.5 mg.
Lowest effective dose	Ongoing	Monthly	The maintenance philosophy: the right dose is the lowest one still producing steady loss.

For women

Reduces oral contraceptive efficacy — the label advises backup contraception for 4 weeks after starting and after each dose increase. Women often titrate slower for nausea; stop well before trying to conceive.

What people actually run

The converged protocol

Start 2.5 mg, hold every step a full 4 weeks minimum, and treat 15 mg as a ceiling you may never need — plenty of people maintain at 5–10 mg. Protein and lifting are mandatory. Women on the pill: barrier backup for 4 weeks after starting and after every dose increase.

Community titration mirrors the label unusually closely for this space, mostly because the label schedule already matches what tolerance allows. The main community amendment is patience: holding a comfortable dose for months rather than climbing on schedule, since the loss keeps coming at mid doses.

The oral contraceptive interaction is the most under-communicated fact about this drug. Tirzepatide slows gastric emptying enough that the label itself advises switching to a non-oral method or adding a barrier method for 4 weeks after initiation and after each dose escalation. An unplanned pregnancy is a much worse side effect than nausea, and this warning reaches almost nobody through marketing.

GI management wisdom is identical to semaglutide: protein first, small meals, fibre and magnesium for constipation, and any dose increase on a week where you can afford a rough Tuesday.

Vial-format product circulates heavily under the vendor label "GLP-2 TZ" — same molecule claimed, zero verification. Since compounding provisions ended in late 2024, vial material is research-chemical grade. Verify concentration before drawing; 30 mg/mL and 10 mg/mL preparations both exist and the same 10-unit draw is a 3× different dose between them.

This is accumulated community practice — years of real-world use across a large number of people, converging on numbers that work. It is not a controlled trial, and for most compounds here no such trial exists or is ever likely to. That makes this the most reliable dosing signal available, and it is a good deal better than guessing.

What the evidence actually says

The honest picture

The evidence here is deep and recent. SURMOUNT-1 randomised 2,539 adults with obesity: 20.9% average weight reduction at 15 mg over 72 weeks, with over half of top-dose participants losing 20% or more. SURPASS-2 beat semaglutide 1 mg head-to-head on both HbA1c and weight. These are large, controlled, published results — the question "does it work" is answered.

What is genuinely open: long-term outcomes. Semaglutide has SELECT's cardiovascular endpoint data behind it; tirzepatide's own outcomes programme is younger, and data beyond a few years of dual-agonist exposure simply does not exist yet.

And the same honesty applies as across the class: averages hide a wide spread of response, regain after stopping is the norm (SURMOUNT-4 measured it directly), and none of the trial data covers the unverified vial-format product a large share of real-world users actually inject.

How it is proposed to work

Tirzepatide is a single peptide engineered to activate two incretin receptors: GLP-1 and GIP. The GLP-1 arm works as in semaglutide — slowed gastric emptying, glucose-dependent insulin secretion, appetite suppression in the brain. What GIP adds is still being worked out; the leading hypotheses involve improved insulin sensitivity in adipose tissue and additional central appetite effects, and possibly a moderating effect on nausea relative to pure GLP-1 agonism at equivalent efficacy.

Whatever the mechanism split, the head-to-head outcome is not subtle: dual agonism outperformed the best pure GLP-1 comparator on every metabolic endpoint tested.

The ~5-day half-life supports weekly dosing, with steady state after about 4 weeks — the pharmacological basis for the 4-week hold per titration step.

When to talk to a doctor first

Most people run Tirzepatide without incident. These are the specific situations where it is worth a conversation with a clinician before you start — not reasons to rule it out, but reasons to go in with your eyes open.

A personal or family history of medullary thyroid carcinoma or MEN2 — the class boxed warning applies to tirzepatide exactly as to semaglutide.
A history of pancreatitis — same class signal, same rule: sudden severe abdominal pain means same-day assessment.
Pregnancy or planning it — stop well in advance and involve the prescriber; rapid weight loss is itself contraindicated in pregnancy. And if you are relying on the pill to prevent pregnancy, read the interaction warning twice.
Severe gastroparesis or major GI disease — this drug slows the stomach by design.
If you take insulin or a sulfonylurea — hypoglycemia risk rises in combination and the other drug usually needs a dose reduction, agreed with the prescriber in advance.
Active gallbladder disease — the rapid-weight-loss gallstone risk applies across the class.

What to expect

Most of what people notice is mild and settles within the first week or two. The list below is ordered by how often it actually comes up, so you know what is routine and what is worth paying attention to.

Common, and usually settles

Nausea, worst in the days after a dose increase and easing with adaptation — generally reported as somewhat milder than semaglutide at equivalent effect.
Constipation or diarrhea — both appear; constipation tends to persist longer.
Reduced appetite beyond intention — eating too little is a real failure mode; protein has to be deliberate.
Fatigue in the first weeks and after step-ups.

Less common

Vomiting — usually a titration-speed signal.
Injection site reactions.
Hair shedding months 3–5, from rapid loss itself; it regrows.
Reflux and burping.

Rare — stop and get advice

Pancreatitis — severe persistent abdominal pain radiating to the back: emergency assessment.
Gallbladder disease — right-upper-quadrant pain after fatty food warrants imaging.
Severe hypoglycemia in combination with insulin or sulfonylureas.
Dehydration-driven kidney injury after persistent vomiting — rehydrate early, escalate if it will not stay down.

Known interactions

Interactions involving Tirzepatide's drug class that DoseIQ screens for. Each one cites where it comes from — an FDA label section or the published record — because an interaction warning you can't trace is just noise.

Serious GLP-1-class + insulin — additive blood-sugar lowering

Semaglutide, tirzepatide and retatrutide all cut appetite and glucose while the insulin dose was sized for the old intake — the mismatch is how hypos happen.

What to do: Prescribers usually reduce insulin when a GLP-1-class drug starts. Monitor glucose closely and have that conversation.

Source: FDA labels, semaglutide/tirzepatide §7

Serious GLP-1-class + sulfonylureas — hypoglycemia risk

Sulfonylureas force insulin release regardless of glucose; adding any GLP-1-class drug on top is the classic hypoglycemia setup.

What to do: The sulfonylurea dose is usually reduced or stopped when a GLP-1-class drug starts — ask your prescriber if that conversation hasn't happened.

Source: FDA labels, semaglutide/tirzepatide §7

Serious Tirzepatide + oral contraceptives — reduced efficacy

Tirzepatide slows gastric emptying enough to reduce oral contraceptive absorption — the label itself says so.

What to do: The label advises a barrier backup for 4 weeks after starting and after each dose increase.

Source: FDA label, tirzepatide §7.1

Caution GH peptides push blood sugar against your diabetes medication

Growth hormone raises glucose and insulin resistance — it works directly against glucose-lowering medication.

What to do: Fasting glucose and HbA1c are worth tracking; medication doses sometimes need adjusting. Your prescriber should know GH peptides are in the picture.

Source: GH pharmacology; tesamorelin label §7

Caution Corticosteroids raise blood sugar against your diabetes medication

Even short prednisone courses raise glucose; diabetes control commonly loosens during a course.

What to do: Monitor glucose during the course; prescribers often adjust doses temporarily.

Source: FDA label, prednisone §7

Caution Slowed stomach emptying can shift this medication's absorption

The whole GLP-1 class — semaglutide, tirzepatide, retatrutide — delays gastric emptying, which changes how narrow-margin oral drugs (thyroid, warfarin, the pill) absorb.

What to do: Keep timing consistent, and re-check the relevant lab (TSH, INR) a few weeks after starting or increasing the dose.

Source: FDA labels, GLP-1 class §7

Caution Weight loss changes thyroid dose needs

Levothyroxine dosing tracks body weight — significant weight loss on any GLP-1-class drug commonly means the old dose becomes too high.

What to do: Re-check TSH after meaningful weight change rather than waiting for symptoms.

Source: Levothyroxine dosing guidance (weight-based)

Caution Stimulant + GLP-1-class — appetite suppressed from both sides

Both suppress appetite; together intake can drop genuinely too low without feeling like anything is wrong.

What to do: Track weight and actually eat protein on schedule — hunger stops being a reliable signal on this combination.

Source: Class pharmacology; widely reported in practice

Caution Beta-blockers mask hypoglycemia warning signs

The racing heart that warns of a low is exactly what a beta-blocker suppresses — lows sneak up quietly.

What to do: Anyone on this combination should know sweating remains a reliable warning sign when the heart rate isn't.

Source: FDA label, metoprolol §7

Caution Lithium + GLP-1-class — dehydration moves lithium levels

Lithium levels track hydration, and a rough titration week — nausea, vomiting, big drops in intake — concentrates lithium.

What to do: Drink deliberately during dose increases, and treat persistent vomiting as a reason to check a lithium level, not just wait out.

Source: Lithium label (volume depletion); GLP-1 class GI profile

Worth knowing Antipsychotic + GLP-1-class — often deliberate, worth tracking

Olanzapine and quetiapine drive weight and glucose up; GLP-1-class drugs are increasingly co-prescribed to counter exactly that.

What to do: Usually intentional — the job here is tracking: fasting glucose, HbA1c and lipids tell you whether the plan is working.

Source: Class pharmacology; current prescribing practice

DoseIQ screens your whole protocol against these rules automatically — every compound, prescription and supplement you track, cross-checked as you add them. Serious flags are always free.

Reconstitution guide

Tirzepatide ships as a lyophilised powder and gets mixed with bacteriostatic water before use. How much water you add sets the concentration, which sets how many syringe units make up each dose. One unit on a U-100 syringe is 0.01 mL — the tables below do the arithmetic for the vial sizes you are most likely to be holding.

30mg vial most common

Water added	Concentration	2.5mg
1mL (common)	30 mg/mL	0.08 mL 8.3 units
2mL	15 mg/mL	0.17 mL 16.7 units

10mg vial

Water added	Concentration	2.5mg
1mL (common)	10 mg/mL	0.25 mL 25 units
2mL	5 mg/mL	0.50 mL 50 units

1.0 mL on a 30 mg vial keeps every label dose inside 50 units and makes the arithmetic clean. The 10 mg vials suit the early titration steps — at 1.0 mL, a 2.5 mg dose is 25 units, easier to read on the syringe.

Commercial pens are ready to use. Compounded vials vary widely — confirm mg/mL with the pharmacy.

Standard steps

Inspect the vialConfirm the label and that the powder cake is intact. Do not use a cracked or compromised vial.
Let it reach room temperatureSitting out for a few minutes reduces condensation inside the vial when the seal is broken.
Disinfect both stoppersWipe the compound vial and the bacteriostatic water vial with a fresh alcohol swab and let them air-dry.
Draw the bacteriostatic waterUse a sterile syringe to draw the volume you have chosen from the reconstitution table.
Add the water down the vial wallInject slowly so it runs down the inside wall rather than spraying directly onto the powder. This limits foaming.
Dissolve gentlySwirl or roll the vial between your hands until the cake dissolves. Never shake — agitation damages peptide bonds. The solution should end up clear.
Label and refrigerateWrite the reconstitution date and concentration on the vial. Store at 2–8°C. Do not freeze.

Running a different vial size or water volume? The DoseIQ calculator works it out for any combination — mcg, mg or IU, on any syringe size.

Timeline and monitoring

Weeks 1–4Appetite suppression arrives early; weight change at 2.5 mg is modest by design.
Weeks 5–24The steep part of the curve through titration — SURMOUNT participants averaged roughly 1% of body weight per week in this phase.
Months 6–18Loss continues longer than most expect; SURMOUNT-1 curves were still falling at 72 weeks at the top doses.
OngoingMaintenance at the settled dose. Withdrawal data (SURMOUNT-4) shows most regain within a year of stopping.

Bloodwork worth discussing

Markers a clinician may consider relevant before or during a protocol. This is context for a conversation, not a self-ordering list.

Marker	Why it is relevant
HbA1c and fasting glucose	Baseline and progress — the glycemic effect is substantial even in non-diabetics.
Lipid panel	Typically improves; worth documenting the before.
Comprehensive metabolic panel	Renal baseline, relevant to the dehydration warning.
TSH if on levothyroxine	Gastric-emptying changes can shift levothyroxine absorption — recheck 6–8 weeks after starting.

Supplies by cycle length

A 30 mg vial provides 12 weeks at 2.5 mg, 6 weeks at 5 mg, 3 weeks at 10 mg, or 2 weeks at 15 mg.

Cycle length	Vials	Syringes	BAC water	Planning note
First 8 weeks (2.5→5 mg)	1 × 30 mg	8 syringes	1 × 10 mL bottle	One vial covers the entire opening two steps.
12 weeks at 10 mg	4 × 30 mg	12 syringes	1 × 10 mL bottle	Plan the refill before the step-up, not after.
12 weeks at 15 mg	6 × 30 mg	12 syringes	1 × 10 mL bottle	The top dose doubles the burn rate of 7.5 mg.

Round up. Priming losses, a dropped syringe or a change of plan all eat into the count.

What the research record contains

SURMOUNT-1 (NEJM, 2022): 2,539 adults with obesity — 20.9% mean weight reduction at 15 mg over 72 weeks versus 3.1% placebo; 57% of top-dose participants lost ≥20%.

SURPASS-2 (NEJM, 2021): head-to-head against semaglutide 1 mg in type 2 diabetes — tirzepatide superior on HbA1c and weight at all three doses tested.

SURMOUNT-4: randomised withdrawal — continuing tirzepatide extended loss; switching to placebo reversed most of it within a year.

Label warnings mirror the class: boxed C-cell tumour warning, pancreatitis, gallbladder disease, hypoglycemia in combination, acute kidney injury on volume loss — plus the §7.1 oral contraceptive interaction that is specific to tirzepatide.

Storage and handling

Pens and vials: refrigerate at 2–8°C; follow the specific product's room-temperature window for in-use pens.
Reconstituted grey-market vials: refrigerate, use within 28–30 days with bacteriostatic water, never freeze.
Label date and concentration on every vial — with 10, 20 and 30 mg vials circulating, the same syringe draw spans a 3× dose range.

Troubleshooting

Nausea after a step-up will not settle.

Drop back one step and hold 4 more weeks. The weight-loss difference between adjacent doses is small; the tolerability difference can be large. There is no prize for reaching 15 mg.

I missed a weekly dose.

Label rule: take it within 4 days, otherwise skip and resume on schedule. Never double.

I am on the pill. What exactly do I do?

Per the label: use a barrier backup, or switch to a non-oral method, for 4 weeks after your first dose AND for 4 weeks after every dose increase. Absorption is the issue, so non-oral methods (IUD, implant, patch, ring) are unaffected.

My vial is labelled "GLP-2 TZ".

That is a vendor alias for tirzepatide, not a different molecule — but nothing about a research-chemical label is verified. Confirm the mg and intended concentration, and treat the first draws from any new vial conservatively.

Stalled at 10 mg.

Audit intake honestly first — appetite adapts and grazing creeps back. If the fundamentals hold, the 12.5 mg step exists. A stall after 15%+ loss is physiology, not failure.

Regulatory status

FDA-approved as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023; obstructive sleep apnea indication added subsequently). Prescription only.

The FDA declared the tirzepatide shortage resolved in late 2024, ending shortage-based compounding; vial product sold since is research-chemical material outside any oversight.

Not a controlled substance. Not WADA-prohibited.

How it compares

Compared with	Difference that matters
Semaglutide	Tirzepatide won the head-to-head (SURPASS-2) and posts higher average loss (~21% vs ~15%). Semaglutide counters with the SELECT cardiovascular outcomes result and no oral-contraceptive warning. On price and access they trade places month to month.
Retatrutide	Retatrutide's Phase 2 average (~24%) is higher still, but it is unapproved and every vial is grey-market. Tirzepatide is the strongest option with a real label behind it.

Frequently asked questions

Is tirzepatide really stronger than semaglutide?

On average, yes — that is a trial result, not marketing. Individually it varies; some people respond better to one than the other, and switching between them is common practice when response disappoints.

Does it affect birth control?

Yes — this is the one GLP-1-class drug whose label says so directly. Barrier backup or a non-oral method for 4 weeks after starting and after each dose increase. IUDs, implants, patches and rings are unaffected.

Why do I lose more slowly than the trial average?

Because an average is not a promise. The SURMOUNT spread ran from non-response to 30%+ loss. Dose, time on drug, protein, sleep and baseline biology all move your position in that spread.

Can I switch from semaglutide?

Commonly done, prescriber-guided, usually landing at a mid-tier tirzepatide dose rather than restarting at 2.5 mg. The transition is not a reason to re-run the whole titration, but it is a reason for a conversation.

What happens when I stop?

SURMOUNT-4 answered this: most of the weight returns within a year on average. Plan maintenance — pharmacological or behavioural — before you stop, not after.

References

SURMOUNT-1 — Tirzepatide Once Weekly for the Treatment of ObesityJastreboff et al., New England Journal of Medicine, 2022
SURPASS-2 — Tirzepatide versus Semaglutide Once Weekly in Type 2 DiabetesFrías et al., New England Journal of Medicine, 2021
Zepbound (tirzepatide) Prescribing Information — §7.1 Oral ContraceptivesU.S. Food and Drug Administration label

Track this in DoseIQ Browse all compounds

This page is an educational research reference and is not medical advice. Dose figures reflect the published record and what the community has converged on — starting points to weigh, not instructions. Consult a qualified healthcare provider before starting any protocol.